A novel two step procedure for immobilizing living cells in microcapsules for improving xenograft survival

Nanocomposite films as electrochemical sensors for detection of catalase activity

Cross-linked hydrogel substrates have garnered attention as they simultaneously enable oxidoreductase reactions in a control volume extended to adsorption of redox capacitors for amplification of electrochemical signals. In this study, the effect of catalase immobilization in mold-casted alginate-based thin films (1 mm × 6 mm × 10 mm) containing multi walled carbon nanotubes (MWCNT) coated with chitosan has been studied via amperometry. The amperometric response was measured as a function of peroxide concentration, at a fixed potential of −0.4 V vs. SPCE in phosphate-buffered saline (pH = 7.4). Results indicate substrate detection is not diffusion-limited by the 100 μm thick chitosan layer, if the cationic polyelectrolyte is in contact with the sensing carbon electrode, and the linear detection of the enzyme absent in solution is enabled by immobilization (R² = 0.9615). The ferricyanide-mediated biosensor exhibited a sensitivity of 4.55 μA/mM for the optimal formulation at room temperature comparable to other nanomaterial hybrid sensing solution namely amine-functionalized graphene with an average response time of 5 s for the optimal formulation. The suitability of the optimized chitosan-coated alginate slabs nano-environment for co-encapsulation of catalase and carbon nanotubes was confirmed by cyclic voltammetry.

Cell encapsulation in core-shell microcapsules through coaxial electrospinning system and horseradish peroxidase-catalyzed crosslinking

Cellular growth of enclosed cells in core-shell microcapsules is a key element for the practical use of the device in tissue engineering and biopharmaceutical fields. We developed alginate derivative microcapsules with a liquid core template by horseradish peroxidase crosslinking using an integrated coaxial microfluidic device by electrospray system. The cells and gelatin solution were extruded from the inner channel of coaxial microfluidic device and alginate possessing phenolic moieties (Alg-Ph) and horseradish peroxidase (HRP) flowed from the outer channel. In open electric filed, concentric drops of the two coaxial fluids broken up into microdrops and sprayed into the gelling bath containing hydrogen peroxide to instantly gel alginate in the shell fluid before the two fluids got mixed or gelatin dispersed in a gelling bath. The core-shell structure of about 350 μm in diameter and gel membrane of 42 μm was developed by optimization of operational parameters including electrical voltage, flow rate and concentration of polymers. The physical properties of microcapsules including swelling and mechanical resistance proved the applicability of fabricated vehicles for cell culture systems in vitro and in vivo. The viability of enclosed fibroblast cells in generated core-shell microcapsule was more than 90% which is sufficiently high compared with it before encapsulation. The growth profile and behavior of cells in microcapsules showed appropriate cell growth and the possibility of fabrication of spherical tissue was confirmed through degradation of hydrogel membrane. These results validate the significant potential of coaxial electrospray system and HRP-mediated hydrogelation in the fabrication of cell-laden core-shell microcapsule for tissue engineering and regenerative medicine.

Effect of artificial cell miniaturization on urea degradation by immobilized E. coli DH5α (pKAU17)

Second generation E. coli DH5α (pKAU17) was successfully encapsulated by means of atomization (MA), inkjet printing (MI) and double-encapsulation (DDMI) for the purpose of urea degradation in a simulated uremic medium at 37 °C. Experimentally determined values of the effectiveness factor are 0.83, 0.28 and 0.34 for the MI, MA and DDMI capsules, respectively, suggesting that the catalytic activity of the E. coli DH5α (pKAU17) immobilized in MI capsule (d = 52 μm ± 2.7 μm) is significantly less diffusion-limited than in the case of the MA (d = 1558 μm ± 125 μm) and DDMI (d = 1370 μm ± 60 μm) bio-encapsulation schemes at the 98.3% CI. The proposed novel double encapsulation biofabrication method for alginate-based microspheres, characterized by lower membrane degradation rates due to secondary containment is recommended compared to the standard atomization scheme currently adopted across immobilization-based therapeutic scenarios. A Fickian-based mechanism is proposed with simulations mimicking urea degradation for a single capsule for the atomization and the inkjet schemes.

Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices

Macroencapsulation technology has been an attractive topic in the field of treatment for Type 1 diabetes due to mechanical stability, versatility, and retrievability of the macro-capsule design. Macro-capsules can be categorized into extravascular and intravascular devices, in which solute transport relies either on diffusion or convection, respectively. Failure of macroencapsulation strategies can be due to limited regenerative capacity of the encased insulin-producing cells, sub-optimal performance of encapsulation biomaterials, insufficient immunoisolation, excessive blood thrombosis for vascular perfusion devices, and inadequate modes of mass transfer to support cell viability and function. However, significant technical advancements have been achieved in macroencapsulation technology, namely reducing diffusion distance for oxygen and nutrients, using pro-angiogenic factors to increase vascularization for islet engraftment, and optimizing membrane permeability and selectivity to prevent immune attacks from host's body. This review presents an overview of existing macroencapsulation devices and discusses the advances based on tissue-engineering approaches that will stimulate future research and development of macroencapsulation technology. Biotechnol. Bioeng. 2016;113: 1381-1402. © 2015 Wiley Periodicals, Inc.

Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine

Cell therapy has achieved tremendous success in regenerative medicine in the past several decades. However, challenges such as cell loss, death and immune-rejection after transplantation still persist. Biomaterials have been designed as carriers to deliver cells to desirable region for local tissue regeneration; as barriers to protect transplanted cells from host immune attack; or as reactors to stimulate host cell recruitment, homing and differentiation. With the assistance of biomaterials, improvement in treatment efficiency has been demonstrated in numerous animal models of degenerative diseases compared with routine free cell-based therapy. Emerging clinical applications of biomaterial assisted cell therapies further highlight their great promise in regenerative therapy and even cure for complex diseases, which have been failed to realize by conventional therapeutic approaches.

Hydrogel Encapsulation of Cells in Core-Shell Microcapsules for Cell Delivery

A newly designed 3D core-shell microcapsule structure composed of a cell-containing liquid core and an alginate hydrogel shell is fabricated using a coaxial dual-nozzle electrospinning system. Spherical alginate microcapsules are successfully generated with a core-shell structure and less than 300 μm in average diameter using this system. The thickness of the core and shell can be easily controlled by manipulating the core and shell flow rates. Cells encapsulated in core-shell microcapsules demonstrate better cell encapsulation and immune protection than those encapsulated in microbeads. The observation of a high percentage of live cells (≈80%) after encapsulation demonstrates that the voltage applied for generation of microcapsules does not significantly affect the viability of encapsulated cells. The viability of encapsulated cells does not change even after 3 d in culture, which suggests that the core-shell structure with culture medium in the core can maintain high cell survival by providing nutrients and oxygen to all cells. This newly designed core-shell structure can be extended to use in multifunctional platforms not only for delivery of cells but also for factor delivery, imaging, or diagnosis by loading other components in the core or shell.

Core-shell hydrogel microcapsules for improved islets encapsulation

Islets microencapsulation holds great promise to treat type 1 diabetes. Currently used alginate microcapsules often have islets protruding outside capsules, leading to inadequate immuno-protection. A novel design of microcapsules with core-shell structures using a two-fluid co-axial electro-jetting is reported. Improved encapsulation and diabetes correction is achieved in a single step by simply confining the islets in the core region of the capsules.

Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain

The concept of using an immunoisolation device to facilitate the transplantation of islets without the need for immunosuppression has been around for more than 50 yr. Significant progress has been made in developing suitable materials that satisfy the need for biocompatibility, durability, and permselectivity. However, the search is ongoing for a device that allows sufficient oxygen transfer while maintaining a barrier to immune cells and preventing rejection of the transplanted tissue. Separating the islets from the rich blood supply in the native pancreas takes its toll. The immunoisolated islets commonly suffer from hypoxia and necrosis, which in turn triggers a host immune response. Efforts have been made to improve the supply of nutrients by using proangiogenic factors to augment the development of a vascular supply in the transplant site, by using small islet cell aggregates to reduce the barrier to diffusion of oxygen, or by creating scaffolds that are in close proximity to a vascular network such as the omental blood supply. Even if these efforts are successful, the shortage of donor islet tissue available for transplantation remains a major problem. To this end, a search for a renewable source of insulin-producing cells is ongoing; whether these will come from adult or embryonic stem cells or xenogeneic sources remains to be seen. Herein we will review the above issues and chart the progress made with various immunoisolation devices in small and large animal models and the small number of clinical trials carried out to date.

Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria

There has been rapid growth in research regarding the use of live bacterial cells for therapeutic purposes. The recognition that these cells can be genetically engineered to synthesize products that have therapeutic potential has generated considerable interest and excitement among clinicians and health professionals. It is expected that a wide range of disease modifying substrates such as enzymes, hormones, antibodies, vaccines, and other genetic products will be used successfully and will impact upon health care substantially. However, a major limitation in the use of these bacterial cells is the complexity of delivering them to the correct target tissues. Oral delivery of live cells, lyophilized cells, and immobilized cells has been attempted but with limited success. Primarily, this is because bacterial cells are incapable of surviving passage through the gastrointestinal tract. In many occasions, when given orally, these cells have been found to provoke immunogenic responses that are undesirable. Recent studies show that these problems can be overcome by delivering live bacterial cells, such as genetically engineered cells, using artificial cell microcapsules. This review summarizes recent advances in the therapeutic use of live bacterial cells for therapy, discusses the principles of using artificial cells for the oral delivery of bacterial cells, outlines methods for preparing suitable artificial cells for this purpose, addresses potentials and limitations for their application in therapy, and provides insight for the future direction of this emergent and highly prospective technology.

Artificial cell bioencapsulation in macro, micro, nano, and molecular dimensions: keynote lecture

Artificial cells now ranges from macro-dimensions, to micron-dimensions, to nano-dimensions, and to molecular dimensions. Those in the macro-dimensions are suitable for use in the bioencapsulation of cells, tissues, microorganisms, and bioreactants. Those in the micron-dimensions are suitable for the bioencapsulation of enzymes, microorganisms, peptides, drugs, vaccine, and other materials. Those in the nano-dimension are being used for blood substitutes and carriers for enzymes, peptides, drugs, etc. Those in the molecular-dimensions are used as blood substitutes, crosslinked enzymes etc.

Increased viability of transplanted hepatocytes when hepatocytes are co-encapsulated with bone marrow stem cells using a novel method

This study is to investigate the viability of hepatocytes when transplanted into Wistar rats using co-encapsulated hepatocytes and bone marrow stem cells. Hepatocytes and bone marrow stem cells, isolated from Wistar rats, are co-encapsulated using either the standard single-step method or a novel two-step cell encapsulation method (www.artcell.mcgill.ca). After intraperitoneal transplantation into Wistar rats, the histology, fate of recovered microcapsules and viability of encapsulated hepatocytes are studied. When prepared using the standard method, there is excellent viability but only for up to 3 weeks. After this, there is extensive fibrous coating and severe fibrous adhesion and no microcapsules can be recovered. On the other hand, using the new two-step encapsulation method, the viability of the encapsulated hepatocytes can be followed for more than 4 months after transplantation. Even up to 4 months, there is significantly less host reaction when using the two-step encapsulation method and 50% of the microcapsules can be recovered. Co-encapsulated with bone marrow stem cells resulted in further increase in viability of the hepatocytes when followed up to 4 months after transplantation. This new approach may improve the potential feasibility of using co-encapsulation of hepatocytes and bone marrow stem cells in bio-artificial liver support for the treatment of liver failure, especially for acute liver failure.

Technology of mammalian cell encapsulation

Entrapment of mammalian cells in physical membranes has been practiced since the early 1950s when it was originally introduced as a basic research tool. The method has since been developed based on the promise of its therapeutic usefulness in tissue transplantation. Encapsulation physically isolates a cell mass from an outside environment and aims to maintain normal cellular physiology within a desired permeability barrier. Numerous encapsulation techniques have been developed over the years. These techniques are generally classified as microencapsulation (involving small spherical vehicles and conformally coated tissues) and macroencapsulation (involving larger flat-sheet and hollow-fiber membranes). This review is intended to summarize techniques of cell encapsulation as well as methods for evaluating the performance of encapsulated cells. The techniques reviewed include microencapsulation with polyelectrolyte complexation emphasizing alginate-polylysine capsules, thermoreversible gelation with agarose as a prototype system, interfacial precipitation and interfacial polymerization, as well as the technology of flat sheet and hollow fiber-based macroencapsulation. Four aspects of encapsulated cells that are critical for the success of the technology, namely the capsule permeability, mechanical properties, immune protection and biocompatibility, have been singled out and methods to evaluate these properties were summarized. Finally, speculations regarding future directions of cell encapsulation research and device development are included from the authors' perspective.

Development of engineered cells for implantation in gene therapy

Human gene therapy is based on the technology of genetic engineering of cells, either through ex vivo or in vivo methods of gene transfer. Many autologous cell types have been successfully modified to deliver recombinant gene products. An alternate form of gene therapy based on genetic modification of non-autologous cells is described. Protection within immuno-isolating devices would allow implantation of well-established recombinant cell lines in different allogeneic hosts, potentially offering a more cost-effective approach to gene therapy. Implantation with microencapsulated fibroblasts and myoblasts has resulted in successful recombinant product delivery in vivo. Correction of disease phenotypes in animal models of human genetic diseases has also been achieved. Cell types such as myoblasts which can differentiate terminally within the implantation device are particularly promising for the future development of this method of gene therapy.

Pharmaceutical and therapeutic applications of artificial cells including microencapsulation

Artificial cells for pharmaceutical and therapeutic applications started as microencapsulation on the micron scale. This has now expanded up to the higher range of macrocapsules and down to the nanometer range of nanocapsules and even to the macromolecular range of cross-linked hemoglobin as blood substitutes. This author first reported microencapsulation of biologically active material in 1957 (T.M.S. Chang, Hemoglobin corpuscles. Research Report for Honours Physiology, Medical Library, McGill University, 1957. (Also reprinted as part of 30th anniversary in Artificial Red Blood Cells Research, J. Biomater. Artif. Cells Artif. Organs 16 (1988) 1-9.) and 1964 (T.M.S. Chang, Semipermeable microcapsules, Science 146 (1964) 524-525). While pharmaceutical research has made use of these approaches for drug delivery, this author has been concentrating on the encapsulation of biotechnological products for therapeutic applications. Therefore, there was little interaction between the two approaches. In the last 10 years, pharmaceutical research, as in other areas of research, has become increasingly interested in biotechnology. Because of this interest, this article is a brief overview of developments of artificial cells for biotechnological products with emphasis on hemoglobin, enzymes, cells and genetically engineered microorganisms.

Artificial cells and bioencapsulation in bioartificial organs

The most common use of artificial cells is for bioencapsulation of biologically active materials. Many combination of materials can be bioencapsulated. The permeability, composition and configurations of artificial cell membrane can be varied using different types of synthetic or biological materials. These possible variations in contents and membranes allow for large variations in the properties and functions of artificial cells.

Artificial cells in immobilization biotechnology

Artificial cells contain biologically active materials. Artificial cells containing adsorbents have been a routine form of treatment in hemoperfusion for patients. This includes acute poisoning, high blood aluminum and iron, and supplement to dialysis in kidney failure. Artificial cells are being tested for use as red blood cell substitutes. Artificial cells encapsulated cell culture are being tested in animals for the treatment of diabetes and liver failure. A novel 2 step method has prevented xenograft rejection. Artificial cells containing enzymes are being studied for treatment in hereditary enzyme deficiency diseases and other diseases. Recent demonstration of extensive enterorecirculation of amino acids in the intestine has allowed its oral administration to deplete specific amino acids. Artificial cells containing complex enzyme system convert wastes like urea and ammonia into essential amino acids. Artificial cell is being used for the production of monoclonal antibodies, interferons and other biotechnological products. It is also being investigated for drug delivery, and for use in other applications in biotechnology, chemical engineering and medicine.